NICE has recommended the drug Lucentis after reversing an earlier decision published in draft guidance, last year. The move was welcomed by the Royal National Institute for the Blind (RNIB), which has campaigned for Lucentis for patients with wet age-related macular degeneration (AMD).
NICE reverses decision on drug for eye disease
NICE recommends the use of Lucentis providing there is evidence of recent progression of the disease and no permanent structural damage to the central fove. It also states that the NHS will only fund 14 injections, with the cost of further injections being met by the manufacturer, Novartis.
